as of 11-20-2026 3:59pm EST
Palisade Bio Inc is a clinical-stage biopharma company focused on identifying and developing therapeutics that protect the integrity of the intestinal barrier. Its portfolio consists of a PALI-2108 for the treatment of IBD, including UC and CD, and is researching PALI-1908.
| Founded: | 1996 | Country: | United States |
| Employees: | N/A | City: | CARLSBAD |
| Market Cap: | 249.2M | IPO Year: | 2019 |
| Target Price: | $8.70 | AVG Volume (30 days): | 2.9M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 10 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.16 | EPS Growth: | 97.06 |
| 52 Week Low/High: | $0.92 - $2.85 | Next Earning Date: | 11-10-2026 |
| Revenue: | $260,000 | Revenue Growth: | 1500.39% |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | -100.00% |
| P/E Ratio: | -5.78 | Index: | |
| Free Cash Flow: | -10847000.0 | FCF Growth: | N/A |
Director
Avg Cost/Share
$1.46
Shares
10,000
Total Value
$14,600.00
Owned After
1,590,294
SEC Form 4
Director
Avg Cost/Share
$1.42
Shares
10,000
Total Value
$14,200.00
Owned After
1,590,294
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Williams Donald Allen | PALI | Director | Oct 2, 2026 | Buy | $1.46 | 10,000 | $14,600.00 | 1,590,294 | |
| Williams Donald Allen | PALI | Director | Oct 1, 2026 | Buy | $1.42 | 10,000 | $14,200.00 | 1,590,294 |
SEC 8-K filings with transcript text
Nov 10, 2026
2 pali-ex99_1.htm
Exhibit 99.1
Palisade Bio Reports Third Quarter 2026 Financial Results and Advances PALI-2108 Phase 2 Clinical Development Programs
First Patient Dosed in Global Phase 2b ASCENTRA-UC Trial; Topline Results Expected in Q4 2027
FDA Clearance Received for Phase 2a ASCENTRA-CD Trial; Initiation of Enrollment Targeted for Q1 2027
New Clinical and Translational Data Presented at ACG and UEG Week 2026 Highlight PALI-2108's Targeted Profile
$113.6 Million in Cash and Cash Equivalents as of September 30, 2026
Denver, CO, November 10, 2026 — Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the “Company”), a clinical-stage biopharmaceutical company developing oral therapies for immune-mediated and fibrotic diseases, today reported financial results for the third quarter ended September 30, 2026, and provided a business update highlighting continued execution of its Phase 2 clinical development strategy for PALI-2108 across inflammatory bowel disease (“IBD”).
“ASCENTRA-UC is now underway, and our focus is on driving enrollment and executing the study to deliver topline results in the fourth quarter of 2027. With nearly all planned U.S. sites activated, we are expanding our global clinical footprint to build on that progress,” said JD Finley, Chief Executive Officer of Palisade Bio. “In parallel, we are preparing to initiate ASCENTRA-CD, with initiation of enrollment targeted for the first quarter of 2027. Our strong financial position supports execution across both programs as we work to establish PALI-2108’s potential as a differentiated, once-daily oral treatment for patients living with IBD.”
Recent Highlights
Initiated Global Phase 2b ASCENTRA-UC Clinical Trial
• Dosed the first patient in ASCENTRA-UC on October 27, 2026, marking an important milestone in the clinical development of PALI-2108 for ulcerative colitis (“UC”).
• Activated 29 of 30 planned U.S. clinical sites, supporting continued enrollment in the study.
• Advanced global expansion toward approximately 115 total sites, with Health Canada CTA clearance received in September 2026, regulatory clearance received in the Republic of Georgia in October 2026 and additional regulatory submissions under review in Europe and other countries.
• ASCENTRA-UC is expected to enroll approximately 204 patients with moderately to severely active UC and evaluate two once-daily oral doses of PALI-2108, 15 mg and 30 mg, compared with placebo.
Exhibit 99.1
• The primary endpoint is clinical remission at Week 12, as measured by the Modified Mayo Score, with secondary endpoints including clinical response, endoscopic improvement and histologic-endoscopic mucosal improvement (“HEMI”).
• Following the 12-week induction period, eligible patients will continue into a 36-week maintenance phase designed to evaluate the durability of remission and response through Week 48.
• Topline results from the 12-week induction period are expected in Q4 2027.
Advanced Phase 2a ASCENTRA-CD Program in Crohn's Disease
• The FDA cleared the IND application for PALI-2108 in Crohn's disease (“CD”) on September 22, 2026, enabling initiation of ASCENTRA-CD.
• ASCENTRA-CD is a multicenter, open-label, single-arm Phase 2a study expected to enroll approximately 60 adults with moderate-to-severe CD.
• The study will evaluate PALI-2108 at a target dose of 30 mg orally once daily.
• The primary endpoint is endoscopic response at Week 12, as defined as a ≥ 50% reduction from baseline in the Simple Endoscopic Score for Crohn’s Disease (“SES-CD”), based on blinded central endoscopic review.
• Initiation of enrollment is targeted for Q1 2027, with the primary efficacy readout expected in Q1 2028.
Presented New Clinical and Translational Data at ACG and UEG Week 2026
• Presented five posters at ACG 2026, including two selected for Presidential Poster Awards, highlighting PALI-2108's clinical, pharmacokinetic, pharmacodynamic and mechanistic profile in inflammatory bowel disease.
• Presented additional clinical and translational findings in one oral presentation and three moderated posters at UEG Week 2026, including endoscopic improvement within two weeks in an exploratory, open-label Phase 1b cohort of five patients with fibrostenotic Crohn's disease and further evidence of targeted intestinal drug exposure.
• Collectively, these findings support the continued phase 2 development of PALI-2108 in UC and CD.
“Now that ASCENTRA-UC is underway, our priority is to maintain enrollment momentum and deliver the clinical data needed to establish PALI-2108’s potential in ulcerative colitis,” said Mitch Jones, M.D., Ph.D., President and Chief Medical Officer of Palisade Bio. “We expect the results to provide a clearer understanding of its ability to induce remission, reduce intestinal inflammation and support sustained disease control. In Crohn’s disease, we are focused on preparing ASCENTRA-CD for initiation of enrollment in the first quarter of 2027.
Aug 10, 2026
May 12, 2026
2 pali-ex99_1.htm
Palisade Bio Reports First Quarter 2026 Financial Results and Highlights Continued Clinical Progress of PALI-2108
Advancing potentially best-in-class once-daily oral, locally-activated PDE4 inhibitor prodrug for treatment of IBD
Phase 2 Ulcerative Colitis (UC) trial expected to commence 3Q 2026
Strong balance sheet expected to support execution through key clinical readouts
Denver, CO, May 12, 2026 — Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade Bio” or the “Company”), a clinical-stage biopharmaceutical company developing next-generation, once-daily, oral PDE4 inhibitor prodrugs designed for targeted delivery to the terminal ileum and colon, today reported financial results for the first quarter ended March 31, 2026 and highlighted continued clinical advancements of its lead program, PALI-2108, including recent data readouts and anticipated Phase 2 trial initiations.
Building on positive Phase 1a and Phase 1b ulcerative colitis cohort data previously reported, the Company recently reported results from the Phase 1b fibrostenotic Crohn’s disease (“FSCD”) cohort, extending the clinical support for the continued development of PALI-2108 across multiple inflammatory bowel disease (“IBD”) indications. The data demonstrated sustained exposure of the active metabolite above IC90 thresholds, along with favorable distribution to colon tissue, supporting consistent target engagement at the site of disease. In addition, pharmacodynamic findings showed modulation of key inflammatory and fibrotic pathways, reinforcing the potential of PALI-2108 to address both components of IBD. The program continues to demonstrate a favorable safety and tolerability profile, reinforcing confidence in the potential of PALI-2108 as it advances into Phase 2 development.
“We continue to see a consistent and differentiated profile emerging for PALI-2108 across IBD,” said JD Finley, Chief Executive Officer of Palisade Bio. “The totality of data generated to date supports our decision to advance into Phase 2 development in both ulcerative colitis and Crohn’s disease. With consistent target engagement, evidence of activity across key inflammatory and fibrotic pathways, and a favorable safety profile, we are increasingly confident in the potential of PALI-2108 as we move into development this year.”
Recent Highlights and Anticipated Milestones
• Completed Phase 1a/b for PALI-2108, Reported Positive Data
✓ Favorable safety and tolerability profile
✓ Evidence of target engagement in ileal and colon tissue
✓ Early signals of clinical activity in Crohn’s disease
• Advancing Toward Phase 2
o IND submission for Phase 2 UC trial expected in 2Q 2026
o IND submission for Phase 2 CD trial expected in 2H 2026
o Phase 2 UC trial initiation targeted for Q3 2026
o Phase 2 CD trial initiation targeted for Q1 2027
• Well-Capitalized Through Potential Key Value Inflection Points
o Phase 2 UC readout (expected in 2H 2027)
o Phase 2 CD readout (expected early 2028)
PALI-2108 is an orally administered, once-daily PDE4 inhibitor prodrug designed for targeted activation in the ileum and colon. Its localized bioactivation is intended to enable sustained target inhibition at the site of inflammation while minimizing systemic exposure and improving tolerability.
Summary of Financial Results
Research and development expenses were $6.4 million for the three months ended March 31, 2026, compared to $1.0 million for the three months ended March 31, 2025. The increase of $5.4 million was primarily attributable to (i) an increase in research and development employee-related expenses, including increased non-cash share-based compensation expense, (ii) a net increase in clinical trial-related expenses associated with the ongoing clinical trials of PALI-2108, and (iii) an increase in chemistry, manufacturing and controls (“CMC”) expenses.
General and administrative expenses were $4.4 million for the three months ended March 31, 2026, compared to $1.4 million for the three months ended March 31, 2025. The increase of $3.0 million was primarily attributable to higher employee-related expenses, including increased non-cash share-based compensation expense, as well as higher professional fees.
As of March 31, 2026, the Company had cash and cash equivalents of $132.6 million and believes that its cash on hand is sufficient to fund its operations through major clinical development milestones, including a Phase 2 primary efficacy readout of PALI-2108 for UC that is expected in the second half of 2027 and a Phase 2 primary efficacy readout of PALI-2108 CD that is expected in early 2028.
About Palisade Bio
Palisade Bio, Inc. (Nasdaq: PALI) is a clinical-stage biopharmaceutical company advancing a next-generation oral PDE4 inhibitor prodrug designed to improve pharmacology, tolerability and convenience for patients with inflammatory and fibrotic diseases. Through its differentia
See how PALI stacks up against similar companies in the market
Enhance your trading experience with our free tools
The information presented on this page, "PALI Palisade Bio Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.